
"Sector" = median of Healthcare across 84 companies
DaVita Inc. is a leading provider of kidney dialysis services for patients with chronic kidney failure or end-stage renal disease. Through its DaVita Kidney Care division, the company operates a network of outpatient dialysis centers and provides related healthcare services, including disease management and clinical research. DaVita also offers acute dialysis services in hospitals and skilled nursing facilities. The company serves approximately 246,000 patients across its centers worldwide.
DaVita generates the vast majority of its revenue from dialysis treatments, which are reimbursed primarily by government programs (Medicare and Medicaid) and commercial insurance plans. The company operates on a fee-for-service model, with each dialysis session billed separately. Revenue is driven by the number of treatments and the payer mix, with higher reimbursement from commercial insurers. DaVita also earns income from ancillary services such as pharmacy, vascular access, and clinical research.
DaVita competes in the medical care facilities industry, specifically within the dialysis services sub-sector. Its primary competitor is Fresenius Medical Care, and together they dominate the U.S. dialysis market. DaVita holds a market share of roughly 35-40% in the U.S. The industry is characterized by high barriers to entry due to regulatory requirements and relationships with nephrologists. DaVita's scale, operational efficiency, and integrated care model provide competitive advantages.
DaVita's primary customers are patients with end-stage renal disease requiring regular dialysis. The company's services are concentrated in the United States, which accounts for the majority of its revenue, with a smaller presence in international markets such as Asia and Europe. DaVita targets both in-center and home dialysis patients, and its payer mix includes government programs (about 70% of revenue) and commercial insurers. The company's growth is tied to the rising prevalence of chronic kidney disease and diabetes.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
Wrqti brings DaVita Inc. data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with DaVita Inc.:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.